Beta vulgaris var. cicla methanol extract prevents the formation of advanced glycation end products and protein oxidation against -glucose, and -fructose-induced protein glycation in vitro

Abstract

Beta vulgaris is an edible plant and herbal medicine traditionally used to treat diabetes and breast cancer and protect against liver damage induced by an HF diet. The aim of this investigation to evaluate the inhibitory activity of B. vulgaris (CH) extract on the formation of advanced glycation end products (AGEs) against fluorescent and Non-fluorescent AGEs, protein oxidation, and protein aggregation in an in vitro model of glucose and fructose protein glycation and Congo red test. Our study provides evidence that CH significantly reduced fluorescent and no fluorescent (Nε-CML) and fructosamine levels in AGEs-BSA systems during four weeks of study. It also avoided protein oxidation, which was shown by the depletion of protein thiol and reduced protein carbonyl, preventing structural loss of protein and AGEs formation by inhibiting protein oxidation and protein glycation. Furthermore, CH extract also inhibited amyloid cross β-structure and increased GPx enzymatic activity. This study demonstrated that CH has a noticeable antiglycation effect in a varied glycation modification of albumin and can retard or forewarn AGEs-related diabetes type 2.